F15599, a highly selective post-synaptic 5-HT1A receptor agonist: In-vivo profile in behavioural models of antidepressant and serotonergic activity

International Journal of Neuropsychopharmacology

Volumn 13, Issue 10, 2010, Pages 1285-1298

  Assié, Marie Bernadette ^a   Bardin, Laurent ^a   Auclair, Agnès L ^a   Carilla Durand, Elisabeth ^a   Depoortère, Ronan ^a   Koek, Wouter ^a   Kleven, Mark S ^a   Colpaert, Francis ^a   Vacher, Bernard ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT syndrome; Corticosterone; F13714; F15599; forced swimming test; ultrasonic vocalization

Indexed keywords

[3 CHLORO 4 FLUOROPHENYL [4 FLUORO 4 [[(5 METHYL 6 METHYLAMINOPYRIDIN 2 YLMETHYL)AMINO]METHYL]PIPERIDIN 1 YLMETHANONE]FUMARATE; [3 CHLORO 4 FLUOROPHENYL [4 FLUORO 4 [[(5 METHYLPYRIMIDIN 2 YLMETHYL)AMINO]METHYL]PIPERIDIN 1 YL]METHANONE]FUMARATE; ANTIDEPRESSANT AGENT; CORTICOSTERONE; F 13714; F 15599; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG; 3 CHLORO 4 FLUOROPHENYL (4 FLUORO 4 (((5 METHYL 6 METHYLAMINOPYRIDIN 2 YLMETHYL)AMINO)METHYL)PIPERIDIN 1 YL)METHANONE; 3 CHLORO 4 FLUOROPHENYL (4 FLUORO 4 (((5 METHYLPYRIMIDIN 2 YLMETHYL)AMINO)METHYL)PIPERIDIN 1 YL)METHANONE; 3-CHLORO-4-FLUOROPHENYL-(4-FLUORO-4-(((5-METHYL-6-METHYLAMINOPYRIDIN-2-YLMETHYL)AMINO)METHYL)PIPERIDIN-1-YL)METHANONE; 3-CHLORO-4-FLUOROPHENYL-(4-FLUORO-4-(((5-METHYLPYRIMIDIN-2-YLMETHYL)AMINO)METHYL)PIPERIDIN-1-YL)METHANONE; AMINOPYRIDINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN; SEROTONIN 1 AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG POTENCY; DRUG STRUCTURE; FORCED SWIMMING TEST; FRONTAL CORTEX; MALE; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; VOCALIZATION; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG EFFECT; HYPOTHERMIA; MOLECULARLY TARGETED THERAPY; MOTOR ACTIVITY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; PREFRONTAL CORTEX; SECRETION; SPRAGUE DAWLEY RAT; SWIMMING; WISTAR RAT;

AMINOPYRIDINES; ANIMALS; ANTIDEPRESSIVE AGENTS; CORTICOSTERONE; DEPRESSION; HYPOTHERMIA; MALE; MODELS, ANIMAL; MOLECULAR TARGETED THERAPY; MOTOR ACTIVITY; PIPERIDINES; PREFRONTAL CORTEX; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; STRESS, PHYSIOLOGICAL; SWIMMING;

EID: 79952662179     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709991222     Document Type: Article

References (51)

1. Artigas F, Adell A, Celada P (2006). Pindolol augmentation of antidepressant response. Current Drug Targets 7, 139-147.
2. Assié M-B, Bardin L, Depoortère R, Carilla-Durand E, Newman-Tancredi A (2006a). F15599, a highly selective serotonin 5-HT1A receptor agonist : in vivo profile in neurochemical and behavioural models of serotonergic activity. European Neuropsychopharmacology 16 (Suppl. 4), S233.
3. Assié M-B, Lomenech H, Ravailhe V, Faucillon V, et al. (2006b). Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat. British Journal of Pharmacology 149, 170-178. (Pubitemid 44360098)
4. Assié M-B, Ravailhe V, Benas C, Newman-Tancredi A (2008). Differential pre- and post-synaptic effects of 5-HT1A receptor agonists: influence on 5-HT levels in hippocampus and on dopamine levels in frontal cortex of freely moving rats. Journal of Psychopharmacology 22 (Suppl. 5), A27.
5. Auclair AL, Bardin L, Depoortère R, Newman-Tancredi A (2007). F15599, a 5-HT1A agonist that preferentially targets post-synaptic receptors in the frontal cortex : III. activity in rodent models of cognition. 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2007. Online. 170.24.
6. Bardin L, Gregoire S, Aliaga M, Malfetes N, et al. (2009). Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. Neuroscience Research. Published online : 1 October 2009. doi:10.1016/ j.neures.2009.10.009.
7. Berendsen HHG, Bourgondien FGM, Broekkamp CLE (1994). Role of dorsal and median raphe nuclei in lower lip retraction in rats. European Journal of Pharmacology 263, 315-318.
8. Berendsen HHG, Jenck F, Broekkamp CL (1989). Selective activation of 5HT1A receptors induces lower lip retraction in the rat. Pharmacology, Biochemistry and Behavior 33, 821-827. (Pubitemid 19284295)
9. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, et al. (2004). Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Molecular Psychiatry 9, 386-392. (Pubitemid 38534699)
10. Bicego KC, Barros RC, Branco LG (2007). Physiology of temperature regulation : comparative aspects. Comparative Biochemistry and Physiology, Part A 147, 616-639. (Pubitemid 46755599)
11. Blier P, Ward NM (2003). Is there a role for 5-HT1A agonists in the treatment of depression? Biological Psychiatry 53, 193-203. (Pubitemid 36135929)
12. Buritova J, Berrichon G, Cathala C, Colpaert FC, et al. (2009). Region-specific changes in 5-HT1A agonist-induced extracellular signal-regulated kinases 1/2 phosphorylation in rat brain : a quantitative ELISA study. Neuropharmacology 56, 350-361.
13. Calogero AE, Bagdy G, Szemeredi K, Tartaglia ME, et al. (1990). Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology 126, 1888-1894. (Pubitemid 20139731)
14. Celada P, Llado L, Assié M-B, Newman-Tancredi A, et al. (2007). F15599, a 5-HT1A agonist that preferentially targets post-synaptic receptors in the frontal cortex : (IV) Influence on rat raphe and pyramidal neuronal activity and cortical dopamine release. 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2007. Online. 170.27.
15. Celada P, Puig M, Amargós-Bosch M, Adell A, et al. (2004). The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. Journal of Psychiatry and Neuroscience 29, 252-265. (Pubitemid 39185866)
16. Colpaert FC, Koek W, Lehmann J, Rivet JM, et al. (1992). S-14506 - a novel, potent, high-efficacy 5-HT1A agonist and potential anxiolytic agent. Drug Development Research 26, 21-48.
17. Compaan JC, Groenink L, Van der Gugten J, Maes RAA, et al. (1997). Pretreatment with 5-HT1A receptor agonist flesinoxan attenuates Fos protein in rat hypothalamus. European Journal of Pharmacology 324, 161-168. (Pubitemid 27174601)
18. Cryan JF, Kelliher P, Kelly JP, Leonard BE (1999). Comparative effects of serotonergic agonists with varying efficacy at the 5-HT1A receptor on core body temperature : modification by the selective 5-HT1A receptor antagonist WAY 100635. Journal of Psychopharmacology 13, 278-283. (Pubitemid 29435789)
19. De Vry J (1995). 5-HT1A receptor agonists : recent developments and controversial issues. Psychopharmacology 121, 1-26.
20. De Vry J, Schreiber R (1993). Comparison of acute and repeated treatment with the 5-HT1A receptor ligands 8-OH-DPAT and ipsapirone in animal models of anxiety and depression. Drug Development Research 30, 91-103.
21. De Vry J, Schreiber R, Melon C, Dalmus M, et al. (2004). 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. European Neuropsychopharmacology 14, 487-495. (Pubitemid 39626897)
22. Detke MJ, Wieland S, Lucki I (1995). Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists. Psychopharmacology 119, 47-54.
23. Drevets WC, Frank E, Price JC, Kupfer DJ, et al. (1999). PET imaging of serotonin 1A receptor binding in depression. Biological Psychiatry 46, 1375-1387.
24. El Yacoubi M, Bouali S, Popa D, Naudon L, et al. (2003). Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proceedings of the National Academy of Sciences USA 100, 6227-6232. (Pubitemid 36576958)
25. Groenink L, Van der Gugten J, Compaan JC, Maes RA, et al. (1997). Flesinoxan pretreatment differentially affects corticosterone, prolactin and behavioural responses to a flesinoxan challenge. Psychopharmacology 131, 93-100. (Pubitemid 27242860)
26. Haddjeri N, Blier P, De Montigny C (1998). Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. Journal of Neuroscience 18, 10150-10156. (Pubitemid 28543788)
27. Haddjeri N, Ortemann C, De Montigny C, Blier P (1999). Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission. European Neuropsychopharmacology 9, 427-440. (Pubitemid 29415723)
28. Julious SA (2004). Using confidence intervals around individual means to assess statistical significance between two means. Pharmaceutical Statistics 3, 217-222. (Pubitemid 39654843)
29. Kelder D, Ross SB (1992). Long lasting attenuation of 8-OH-DPAT-induced corticosterone secretion after a single injection of a 5-HT1A receptor agonist. Naunyn-Schmiedebergs Archives of Pharmacology 346, 121-126.
30. Kenakin T (2007). Functional selectivity through protean and biased agonism: who steers the ship? Molecular Pharmacology 72, 1393-1401 (Pubitemid 350146075)
31. Kleven MS, Koek W (1996). Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics 0.1. Antipunishment effects in the pigeon. Journal of Pharmacology and Experimental Therapeutics 276, 388-397.
32. Koek W, Patoiseau JF, Assié M-B, Cosi C, et al. (1998). F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. Journal of Pharmacology and Experimental Therapeutics 287, 266-283. (Pubitemid 29140211)
33. Koek W, Vacher B, Cosi C, Assié M-B, et al. (2001). 5-HT1A receptor activation and antidepressant-like effects : F 13714 has high efficacy and marked antidepressant potential. European Journal of Pharmacology 420, 103-112. (Pubitemid 32537684)
34. Lemoine L, Verdurand M, Vacher B, Blanc E, et al. (2009). Synthesis, fluorine-18 labelling and radiopharmacological evaluation of F15599, a novel 5-HT1A receptor agonist. Journal of Nuclear Medicine 49 (Suppl. 1), 285P.
35. Mannoury la Cour C, El Mestikawy S, Hanoun N, Hamon M, et al. (2006). Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Molecular Pharmacology 70, 1013-1021. (Pubitemid 44268458)
36. Matheson GK, Raess BU, Tunnicliff G (1996). Effects of repeated doses of azapirones on rat brain 5-HT1A receptors and plasma corticosterone levels. General Pharmacology 27, 355-361.
37. Millan MJ, Rivet JM, Canton H, Le Marouille Girardon S, et al. (1993). Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat : a pharmacological characterization of the actions of novel agonists and antagonists. Journal of Pharmacology and Experimental Therapeutics 264, 1364-1376. (Pubitemid 23318633)
38. Miller JM, Brennan KG, Ogden TR, Oquendo MA, et al. (2009). Elevated serotonin 1A binding in remitted major depressive disorder : evidence for a trait biological abnormality. Neuropsychopharmacology 34, 2275-2284.
39. Miquel MC, Doucet E, Boni C, El Mestikawy S, et al. (1991). Central serotonin1A receptors - respective distributions of encoding messenger RNA, receptor protein and binding sites by in situ hybridization histochemistry, radioimmunohistochemistry and autoradiographic mapping in the rat brain. Neurochemistry International 19, 453-465.
40. Motulsky HJ, Christopoulos A (2003). Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting. San Diego, CA: GraphPad Software Inc.
41. Naudon L, El Yacoubi M, Vaugeois JM, Leroux-Nicollet I, et al. (2002). A chronic treatment with fluoxetine decreases 5-HT1A receptors labeling in mice selected as a genetic model of helplessness. Brain Research 936, 68-75. (Pubitemid 34461934)
42. Newman-Tancredi A, Martel JC, Assié M-B, Buritova J, et al. (2009). Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. British Journal of Pharmacology 156, 338-353.
43. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, et al. (2006). Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biological Psychiatry 59, 106-113. (Pubitemid 43117499)
44. Sanchez C (2003). Stress-induced vocalisation in adult animals. A valid model of anxiety? European Journal of Pharmacology 463, 133-143. (Pubitemid 36205076)
45. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, et al. (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635 - effects of depression and antidepressant treatment. Archives of General Psychiatry 57, 174-180. (Pubitemid 30075269)
46. Savitz J, Lucki I, Drevets WC (2009). 5-HT1A receptor function in major depressive disorder. Progress in Neurobiology 88, 17-31.
47. Shao J, Tu D (1995). The Jackknife and Bootstrap. New York: Springer Verlag Inc.
48. Sullivan GM, Ogden RT, Oquendo MA, Kumar JS, et al. (2009). Positron emission tomography quantification of serotonin-1. A receptor binding in medication-free bipolar depression. Biological Psychiatry 66, 223-230.
49. Szewczyk B, Albert PR, Burns AM, Czesak M, et al. (2009). Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. International Journal of Neuropsychopharmacology 12, 155-168.
50. Tricklebank MD, Forler C, Fozard JR (1984). The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. European Journal of Pharmacology 106, 271-282. (Pubitemid 15210616)
51. Wieland S, Lucki I (1990). Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 101, 497-504. (Pubitemid 20220042)